$17,354.58 consulting Payment -- Boehringer Ingelheim to Dr. Kevin Hill

Boehringer Ingelheim pays Internal Medicine physician $17,354.58 for consulting services

This page provides a detailed analysis of a $17,354.58 consulting payment from Boehringer Ingelheim to Dr. Kevin Hill. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$17,354.58
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyBoehringer Ingelheim
PhysicianDr. Kevin Hill
NPI Number1807108169
Physician SpecialtyInternal Medicine
LocationLos Angeles, CA
Date of Payment2024-09-05
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Boehringer Ingelheim made a $17.4K consulting payment to Kevin Hill, a Internal Medicine specialist in Los Angeles, CA. Boehringer Ingelheim paid Dr. Kevin Hill $17,354.58 for consulting services on September 5, 2024. The payment was categorized as a 'Consulting Fee' under the 'consulting' payment type. Dr. Hill, an Internal Medicine specialist located in Los Angeles, CA, received this payment.

Patient Guidance: What This Payment Means for You

If you are a patient of Dr. Kevin Hill, this payment relates to his professional services and does not directly impact your care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

For an Internal Medicine specialist, consulting fees from pharmaceutical companies are common, but the amount of $17,354.58 may be higher than typical for a single engagement.

Regulatory Context: Sunshine Act Requirements

This payment is subject to disclosure under the Sunshine Act, requiring pharmaceutical companies to report payments made to physicians and teaching hospitals.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $17.4K payment for?

This was a consulting payment of $17.4K from Boehringer Ingelheim to Kevin Hill, categorized as "Consulting Fee". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Kevin Hill accept pharmaceutical money?

Yes, Kevin Hill received this $17.4K payment from Boehringer Ingelheim. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Kevin Hill's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $17.4K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Internal Medicine?

To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Kevin Hill's relationship with Boehringer Ingelheim?

The payment amount is substantial for a single consulting engagement. This $17.4K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Internal Medicine?

The payment date is recent, falling within the current reporting year.

What should patients do after learning about this payment?

If you are a patient of Dr. Kevin Hill, this payment relates to his professional services and does not directly impact your care.

What else should I know about this consulting payment?

The payment was made by a major pharmaceutical company, Boehringer Ingelheim.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.